KR20090055562A - 오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체 - Google Patents
오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체 Download PDFInfo
- Publication number
- KR20090055562A KR20090055562A KR1020097004339A KR20097004339A KR20090055562A KR 20090055562 A KR20090055562 A KR 20090055562A KR 1020097004339 A KR1020097004339 A KR 1020097004339A KR 20097004339 A KR20097004339 A KR 20097004339A KR 20090055562 A KR20090055562 A KR 20090055562A
- Authority
- KR
- South Korea
- Prior art keywords
- anticancer
- methyl
- trans
- substituted
- pharmaceutically acceptable
- Prior art date
Links
- 0 Cc1n[n]c(*)c1 Chemical compound Cc1n[n]c(*)c1 0.000 description 7
- DPEBBCAUDJKSMD-AJHAWQTOSA-N CC(C)(C)[n]1nccc1Nc1nc(C[C@](CC2)(CC[C@H]2Oc(cccc2C(F)(F)F)c2F)C(NN)=O)ccc1 Chemical compound CC(C)(C)[n]1nccc1Nc1nc(C[C@](CC2)(CC[C@H]2Oc(cccc2C(F)(F)F)c2F)C(NN)=O)ccc1 DPEBBCAUDJKSMD-AJHAWQTOSA-N 0.000 description 1
- IPWMISUPZRDFIM-RYECUYIGSA-N CC(C)(C)[n]1nccc1Nc1nc(C[C@](CC2)(CC[C@H]2Sc(cccc2Cl)c2Cl)C(OC(C)(C)C)=O)ccc1 Chemical compound CC(C)(C)[n]1nccc1Nc1nc(C[C@](CC2)(CC[C@H]2Sc(cccc2Cl)c2Cl)C(OC(C)(C)C)=O)ccc1 IPWMISUPZRDFIM-RYECUYIGSA-N 0.000 description 1
- QOTJPJGBOWWFBB-UHFFFAOYSA-N CC(C)(C)[n]1nccc1Nc1nc(Cl)cnc1 Chemical compound CC(C)(C)[n]1nccc1Nc1nc(Cl)cnc1 QOTJPJGBOWWFBB-UHFFFAOYSA-N 0.000 description 1
- NNXROHRFMWHXNH-UHFFFAOYSA-N CC(O1)=NNC1=O Chemical compound CC(O1)=NNC1=O NNXROHRFMWHXNH-UHFFFAOYSA-N 0.000 description 1
- ZVGKPQCCKGLQPB-UHFFFAOYSA-N CC(O1)=NNC1=S Chemical compound CC(O1)=NNC1=S ZVGKPQCCKGLQPB-UHFFFAOYSA-N 0.000 description 1
- ABMOCWDAAHNGED-UHFFFAOYSA-N CC1N=CN(C)C1 Chemical compound CC1N=CN(C)C1 ABMOCWDAAHNGED-UHFFFAOYSA-N 0.000 description 1
- WFJYZRKNRWYRTN-BCTVQRCUSA-N CN1N=C([C@](Cc2cccc(Nc3n[nH]cc3)n2)(CC2)CC[C@@H]2Oc(cccc2Cl)c2F)OC1=O Chemical compound CN1N=C([C@](Cc2cccc(Nc3n[nH]cc3)n2)(CC2)CC[C@@H]2Oc(cccc2Cl)c2F)OC1=O WFJYZRKNRWYRTN-BCTVQRCUSA-N 0.000 description 1
- BAMPVSWRQZNDQC-UHFFFAOYSA-N Cc1c(C)[s]c(C)n1 Chemical compound Cc1c(C)[s]c(C)n1 BAMPVSWRQZNDQC-UHFFFAOYSA-N 0.000 description 1
- PUMREIFKTMLCAF-UHFFFAOYSA-N Cc1c[o]cn1 Chemical compound Cc1c[o]cn1 PUMREIFKTMLCAF-UHFFFAOYSA-N 0.000 description 1
- QMHIMXFNBOYPND-UHFFFAOYSA-N Cc1c[s]cn1 Chemical compound Cc1c[s]cn1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 1
- NSAUQTCATRWAJC-UHFFFAOYSA-N Cc1cnc(C)[o]1 Chemical compound Cc1cnc(C)[o]1 NSAUQTCATRWAJC-UHFFFAOYSA-N 0.000 description 1
- FZAXBPZVVJOFKX-UHFFFAOYSA-N Cc1n[o]cn1 Chemical compound Cc1n[o]cn1 FZAXBPZVVJOFKX-UHFFFAOYSA-N 0.000 description 1
- IBANRDPEOYZVGW-UHFFFAOYSA-N Cc1n[s]cn1 Chemical compound Cc1n[s]cn1 IBANRDPEOYZVGW-UHFFFAOYSA-N 0.000 description 1
- QLXOJLUHWBDVKZ-UHFFFAOYSA-O Cc1nc[nH+][s]1 Chemical compound Cc1nc[nH+][s]1 QLXOJLUHWBDVKZ-UHFFFAOYSA-O 0.000 description 1
- PZKFSRWSQOQYNR-UHFFFAOYSA-N Cc1ncn[nH]1 Chemical compound Cc1ncn[nH]1 PZKFSRWSQOQYNR-UHFFFAOYSA-N 0.000 description 1
- RGTBLCLLSZPOKR-UHFFFAOYSA-N Cc1ncn[o]1 Chemical compound Cc1ncn[o]1 RGTBLCLLSZPOKR-UHFFFAOYSA-N 0.000 description 1
- LSEAAPGIZCDEEH-UHFFFAOYSA-N Clc1nc(Cl)cnc1 Chemical compound Clc1nc(Cl)cnc1 LSEAAPGIZCDEEH-UHFFFAOYSA-N 0.000 description 1
- LLROFEFDEFKWQN-CWSKOGRWSA-N O=C1OC([C@](Cc2cccc(Nc3n[nH]cc3)n2)(CC2)CC[C@@H]2Oc(cccc2Cl)c2F)=NN1 Chemical compound O=C1OC([C@](Cc2cccc(Nc3n[nH]cc3)n2)(CC2)CC[C@@H]2Oc(cccc2Cl)c2F)=NN1 LLROFEFDEFKWQN-CWSKOGRWSA-N 0.000 description 1
- USUYXDKUCNQBKM-CWSKOGRWSA-N O=C1OC([C@](Cc2cccc(Nc3n[nH]cc3)n2)(CC2)CC[C@@H]2Sc(cccc2Cl)c2Cl)=NN1 Chemical compound O=C1OC([C@](Cc2cccc(Nc3n[nH]cc3)n2)(CC2)CC[C@@H]2Sc(cccc2Cl)c2Cl)=NN1 USUYXDKUCNQBKM-CWSKOGRWSA-N 0.000 description 1
- WOMKQOXPOGODKV-VVONHTQRSA-N OC([C@](Cc1cccc(Nc2n[nH]cc2)n1)(CC1)CC[C@@H]1Sc(cccc1Cl)c1Cl)=O Chemical compound OC([C@](Cc1cccc(Nc2n[nH]cc2)n1)(CC1)CC[C@@H]1Sc(cccc1Cl)c1Cl)=O WOMKQOXPOGODKV-VVONHTQRSA-N 0.000 description 1
- XTAXEKXLQMGPLX-HNSKJHPRSA-N OC([C@](Cc1cncc(Nc2n[nH]cc2)n1)(CC1)CC[C@@H]1Oc(cccc1Cl)c1F)=O Chemical compound OC([C@](Cc1cncc(Nc2n[nH]cc2)n1)(CC1)CC[C@@H]1Oc(cccc1Cl)c1F)=O XTAXEKXLQMGPLX-HNSKJHPRSA-N 0.000 description 1
- XDNSNYQCQYHRRT-VFTOWQEXSA-N OC1OC([C@](Cc2cccc(Nc3n[nH]cc3)n2)(CC2)CC[C@@H]2S(c(cccc2Cl)c2Cl)(=O)=O)=NN1 Chemical compound OC1OC([C@](Cc2cccc(Nc3n[nH]cc3)n2)(CC2)CC[C@@H]2S(c(cccc2Cl)c2Cl)(=O)=O)=NN1 XDNSNYQCQYHRRT-VFTOWQEXSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C07D241/22—Benzenesulfonamido pyrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2006-236472 | 2006-08-31 | ||
| JP2006236472 | 2006-08-31 | ||
| US92608607P | 2007-04-25 | 2007-04-25 | |
| US60/926,086 | 2007-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090055562A true KR20090055562A (ko) | 2009-06-02 |
Family
ID=39136042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097004339A KR20090055562A (ko) | 2006-08-31 | 2007-08-29 | 오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7915263B2 (ja) |
| EP (2) | EP2062887B1 (ja) |
| JP (3) | JP2008081492A (ja) |
| KR (1) | KR20090055562A (ja) |
| CN (1) | CN101528731B (ja) |
| AR (1) | AR062585A1 (ja) |
| AU (1) | AU2007289609B2 (ja) |
| CA (1) | CA2657469C (ja) |
| CL (1) | CL2007002519A1 (ja) |
| CO (1) | CO6190529A2 (ja) |
| CR (1) | CR10553A (ja) |
| EC (1) | ECSP099062A (ja) |
| ES (1) | ES2389515T3 (ja) |
| GT (1) | GT200900008A (ja) |
| HN (1) | HN2009000113A (ja) |
| IL (1) | IL196497A0 (ja) |
| MA (1) | MA30719B1 (ja) |
| MX (1) | MX2009000390A (ja) |
| NO (1) | NO20091301L (ja) |
| NZ (1) | NZ574081A (ja) |
| PE (1) | PE20080835A1 (ja) |
| RU (1) | RU2437880C2 (ja) |
| SV (1) | SV2009003152A (ja) |
| TW (1) | TW200817363A (ja) |
| UA (1) | UA95972C2 (ja) |
| WO (2) | WO2008026769A1 (ja) |
| ZA (1) | ZA200900126B (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2254888B1 (en) * | 2008-02-22 | 2014-12-24 | Msd K.K. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| CA2720034A1 (en) * | 2008-03-31 | 2009-10-08 | Sun Pharmaceutical Industries Ltd. | An improved process for the preparation of morphinane analogues |
| US20110129467A1 (en) * | 2008-07-24 | 2011-06-02 | Nerviano Medical Sciences S.R.L. | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
| AU2010284255B2 (en) * | 2009-08-17 | 2016-11-17 | Memorial Sloan-Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| US9145414B2 (en) | 2011-09-30 | 2015-09-29 | Taiho Pharmaceutical Co., Ltd. | 1,2,4-triazine-6-carboxamide derivative |
| TWI485146B (zh) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| EA201692155A1 (ru) | 2014-05-13 | 2017-04-28 | Мемориал Слоун-Кеттеринг Кэнсэ Сентр | МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| TWI693218B (zh) | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光ａ激酶抑制劑 |
| US10866838B2 (en) * | 2015-03-25 | 2020-12-15 | Intel Corporation | Cluster computing service assurance apparatus and method |
| CN108250191B (zh) * | 2018-03-15 | 2020-10-20 | 兰州大学 | 一种3,5-二取代的2-氨基-吡嗪化合物及其制备工艺与应用 |
| WO2020049208A1 (es) | 2018-09-09 | 2020-03-12 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida |
| CN112898292A (zh) * | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
| TWI785474B (zh) * | 2020-01-22 | 2022-12-01 | 大陸商北京加科思新藥研發有限公司 | 用作選擇性Aurora A抑制劑的新型雜環化合物 |
| WO2023196887A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA07174A (fr) | 1981-08-24 | 1984-04-30 | May & Baker Ltd | Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent. |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5223608A (en) | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| ES2137932T3 (es) | 1990-09-28 | 2000-01-01 | Smithkline Beecham Corp | Procedimiento para la preparacion de analogos de camptotecina solubles en agua, asi como los compuestos 10-hidroxi-11-alcoxi-6-camptotecina. |
| US5247089A (en) | 1990-12-20 | 1993-09-21 | North Carolina State University | Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US5191082A (en) | 1990-12-20 | 1993-03-02 | North Carolina State University | Camptothecin intermediate and method of making camptothecin intermediates |
| US5243050A (en) | 1990-12-20 | 1993-09-07 | North Carolina State University | Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US5200524A (en) | 1990-12-20 | 1993-04-06 | North Carolina State University | Camptothecin intermediates and method of making same |
| US5162532A (en) | 1990-12-20 | 1992-11-10 | North Carolina State University | Intermediates and method of making camptothecin and camptothecin analogs |
| DE69233803D1 (de) | 1992-10-28 | 2011-03-31 | Genentech Inc | Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten |
| JP3025602B2 (ja) | 1993-05-21 | 2000-03-27 | デビオファーム エス．アー． | 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法 |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| JP3154399B2 (ja) | 1996-07-04 | 2001-04-09 | デビオファーム エス．アー． | 白金化合物の製造方法 |
| PE92198A1 (es) | 1996-08-01 | 1999-01-09 | Banyu Pharma Co Ltd | Derivados de 1,4-piperidina disustituida que contienen fluor |
| ES2250186T3 (es) | 1999-09-10 | 2006-04-16 | MERCK & CO., INC. | Inhibidores de tirosina quinasa. |
| AU2002213467A8 (en) | 2000-10-11 | 2009-07-30 | Chemocentryx Inc | Modulation of ccr4 function |
| US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| ATE528303T1 (de) | 2000-12-21 | 2011-10-15 | Vertex Pharma | Pyrazoleverbindungen als proteinkinasehemmer |
| WO2002094264A1 (en) | 2001-05-23 | 2002-11-28 | Tularik Inc. | Ccr4 antagonists |
| US7709475B2 (en) * | 2004-05-21 | 2010-05-04 | Banyu Pharmaceutical Co., Ltd. | Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton |
| US7491720B2 (en) * | 2004-10-29 | 2009-02-17 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having Aurora A selective inhibitory action |
| US7919487B2 (en) | 2004-11-10 | 2011-04-05 | Synta Pharmaceuticals Corporation | Heteroaryl compounds |
| GB0428082D0 (en) | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| US20060160869A1 (en) | 2005-01-05 | 2006-07-20 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| JP5075624B2 (ja) * | 2005-04-28 | 2012-11-21 | 田辺三菱製薬株式会社 | シアノピリジン誘導体及びその医薬としての用途 |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| WO2006129842A1 (ja) * | 2005-06-01 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
-
2007
- 2007-04-26 JP JP2007116649A patent/JP2008081492A/ja not_active Withdrawn
- 2007-08-29 WO PCT/JP2007/067251 patent/WO2008026769A1/ja active Application Filing
- 2007-08-29 UA UAA200902851A patent/UA95972C2/ru unknown
- 2007-08-29 EP EP07806706A patent/EP2062887B1/en active Active
- 2007-08-29 US US11/897,272 patent/US7915263B2/en active Active
- 2007-08-29 CL CL200702519A patent/CL2007002519A1/es unknown
- 2007-08-29 EP EP07806705A patent/EP2061782A4/en not_active Withdrawn
- 2007-08-29 TW TW096132117A patent/TW200817363A/zh unknown
- 2007-08-29 AU AU2007289609A patent/AU2007289609B2/en not_active Ceased
- 2007-08-29 NZ NZ574081A patent/NZ574081A/en not_active IP Right Cessation
- 2007-08-29 PE PE2007001171A patent/PE20080835A1/es not_active Application Discontinuation
- 2007-08-29 AR ARP070103835A patent/AR062585A1/es unknown
- 2007-08-29 RU RU2009111599/04A patent/RU2437880C2/ru not_active IP Right Cessation
- 2007-08-29 KR KR1020097004339A patent/KR20090055562A/ko not_active Application Discontinuation
- 2007-08-29 ES ES07806706T patent/ES2389515T3/es active Active
- 2007-08-29 US US12/310,307 patent/US20100016335A1/en not_active Abandoned
- 2007-08-29 MX MX2009000390A patent/MX2009000390A/es active IP Right Grant
- 2007-08-29 WO PCT/JP2007/067250 patent/WO2008026768A1/en active Application Filing
- 2007-08-29 JP JP2008532150A patent/JP4466782B2/ja active Active
- 2007-08-29 CA CA2657469A patent/CA2657469C/en not_active Expired - Fee Related
- 2007-08-29 CN CN200780032242.7A patent/CN101528731B/zh not_active Expired - Fee Related
-
2009
- 2009-01-07 ZA ZA200900126A patent/ZA200900126B/xx unknown
- 2009-01-13 CR CR10553A patent/CR10553A/es not_active Application Discontinuation
- 2009-01-13 GT GT200900008A patent/GT200900008A/es unknown
- 2009-01-13 HN HN2009000113A patent/HN2009000113A/es unknown
- 2009-01-13 IL IL196497A patent/IL196497A0/en unknown
- 2009-01-13 EC EC2009009062A patent/ECSP099062A/es unknown
- 2009-01-14 SV SV2009003152A patent/SV2009003152A/es unknown
- 2009-01-14 CO CO09002429A patent/CO6190529A2/es not_active Application Discontinuation
- 2009-03-20 MA MA31731A patent/MA30719B1/fr unknown
- 2009-03-30 NO NO20091301A patent/NO20091301L/no not_active Application Discontinuation
- 2009-10-29 JP JP2009248400A patent/JP5256168B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20090055562A (ko) | 오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체 | |
| EP1828165B1 (en) | Novel aminopyridine derivatives having aurora a selective inhibitory action | |
| EP2411010B1 (en) | Novel aminopyridine derivatives having aurora a selective inhibitory action | |
| EP2254888B1 (en) | Novel aminopyridine derivatives having aurora a selective inhibitory action | |
| US8263632B2 (en) | Aminopyridine derivatives having Aurora A selective inhibitory action | |
| EP2017279B1 (en) | Aminopyrimidine derivatives having aurora-a-selective inhibitory activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| N231 | Notification of change of applicant | ||
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |